Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017

  • ID: 4318751
  • Drug Pipelines
  • Region: Middle East
  • 56 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Atriva Therapeutics GmbH
  • Fab'entech SA
  • Gilead Sciences Inc
  • Humabs BioMed SA
  • Nanotherapeutics Inc
  • NanoViricides Inc
  • MORE
Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERSCoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Atriva Therapeutics GmbH
  • Fab'entech SA
  • Gilead Sciences Inc
  • Humabs BioMed SA
  • Nanotherapeutics Inc
  • NanoViricides Inc
  • MORE
  1. Introduction
  2. Middle East Respiratory Syndrome (MERS) - Overview
  3. Middle East Respiratory Syndrome (MERS) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
  15. Atriva Therapeutics GmbH
  16. Autoimmune Technologies LLC
  17. Fab'entech SA
  18. Gilead Sciences Inc
  19. Humabs BioMed SA
  20. Inovio Pharmaceuticals Inc
  21. Nanotherapeutics Inc
  22. NanoViricides Inc
  23. Novavax Inc
  24. Phelix Therapeutics LLC
  25. Planet Biotechnology Inc
  26. Regeneron Pharmaceuticals Inc
  27. Romark Laboratories LC
  28. Middle East Respiratory Syndrome (MERS) - Drug Profiles
  29. 3B-11 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. ATR-006 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. BNSP-333S1 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. CSW-1 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. FBR-001 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. FM-2101 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. GS-5734 - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. INO-4500 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. LCA-60 - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. Middle East respiratory syndrome coronavirus vaccine - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. Middle East respiratory syndrome coronavirus vaccine - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. Middle East respiratory syndrome vaccine - Drug Profile
  78. Product Description
  79. Mechanism Of Action
  80. R&D Progress
  81. Middle East respiratory syndrome vaccine - Drug Profile
  82. Product Description
  83. Mechanism Of Action
  84. R&D Progress
  85. Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
  86. Product Description
  87. Mechanism Of Action
  88. R&D Progress
  89. nitazoxanide - Drug Profile
  90. Product Description
  91. Mechanism Of Action
  92. R&D Progress
  93. REGN-3048 - Drug Profile
  94. Product Description
  95. Mechanism Of Action
  96. R&D Progress
  97. REGN-3051 - Drug Profile
  98. Product Description
  99. Mechanism Of Action
  100. R&D Progress
  101. SAB-301 - Drug Profile
  102. Product Description
  103. Mechanism Of Action
  104. R&D Progress
  105. Small Molecule for Middle East Respiratory Syndrome - Drug Profile
  106. Product Description
  107. Mechanism Of Action
  108. R&D Progress
  109. Middle East Respiratory Syndrome (MERS) - Product Development Milestones
  110. Featured News & Press Releases
  111. Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300
  112. Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
  113. Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment
  114. Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
  115. Appendix
  116. Methodology
  117. Coverage
  118. Secondary Research
  119. Primary Research
  120. Expert Panel Validation
  121. Contact Us
  122. Disclaimer
List of Tables
  1. Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H1
  11. Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H1
  12. Middle East Respiratory Syndrome (MERS) - Pipeline by Fab'entech SA, H1
  13. Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H1
  14. Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H1
  15. Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H1
  16. Middle East Respiratory Syndrome (MERS) - Pipeline by Nanotherapeutics Inc, H1
  17. Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H1
  18. Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H1
  19. Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H1
  20. Middle East Respiratory Syndrome (MERS) - Pipeline by Planet Biotechnology Inc, H1
  21. Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H1
  22. Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H1
List of Figures
  1. Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Atriva Therapeutics GmbH
  • Autoimmune Technologies LLC
  • Fab'entech SA
  • Gilead Sciences Inc
  • Humabs BioMed SA
  • Inovio Pharmaceuticals Inc
  • Nanotherapeutics Inc
  • NanoViricides Inc
  • Novavax Inc
  • Phelix Therapeutics LLC
  • Planet Biotechnology Inc
  • Regeneron Pharmaceuticals Inc
  • Romark Laboratories LC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll